TABLE 1.
The characteristic of randomized controlled trials enrolled
| Study ID | Phase | Drug | Administration | Dosage | Outcomes |
|---|---|---|---|---|---|
| Olesen et al. (2004) | 2a | Olcegepant | Intravenous infusion single dose | 2.5 mg | ①, ⑤, ⑦ |
| Ho, Ferrari, et al. (2008) | 3 | Telcagepant | Oral single dose | 150 mg/300 mg | ①, ②, ③, ④, ⑤, ⑦, ⑧ |
| Ho, Mannix, et al., (2008) | 2 | Telcagepant | Oral single dose | 300, 400, and 600 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Connor et al. (2009) | 3 | Telcagepant | Oral single dose | 150, 300 mg | ①, ②, ③, ④, ⑤, ⑦ |
| Ho et al. (2010) | 3 | Telcagepant | Oral single dose | 140, 280 mg | ①, ②, ③, ④, ⑤, ⑦ |
| Diener et al. (2011) | 2a | BI 44370 TA | Oral single dose | 400 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Hewitt, Aurora, et al. (2011) | 2a | MK‐3207 | Oral single dose | 10, 100, 200 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Hewitt, Martin, et al. (2011) | 3 | Telcagepant | Oral single dose | 280 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Ho et al. (2012) | 3 | Telcagepant | Oral single dose | 280 mg tablet/300 mg capsule | ①, ②, ③, ④, ⑤, ⑥, ⑦, ⑧ |
| Marcus et al. (2014) | 2b | Rimegepant | Oral single dose | 75, 150, and 300 mg | ①, ②, ③, ④, ⑦, ⑧ |
| Voss et al. (2016) | 2b | Ubrogepant | Oral single dose | 25, 50, and 100 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦, ⑧ |
| Croop et al. (2019) | 3 | Rimegepant | Oral single dose | 75 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Dodick et al. (2019) | 3 | Ubrogepant | Oral single dose | 50 and 100 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
| Lipton, Croop, et al. (2019) | 3 | Rimegepant | Oral single dose | 75 mg | ①, ②, ③, ④, ⑤, ⑦ |
| Lipton, Dodick, et al. (2019) | 3 | Ubrogepant | Oral single dose | 25 and 50 mg | ①, ②, ③, ④, ⑤, ⑥, ⑦ |
①, Pain freedom 2 hr postdose; ②, Nausea freedom 2 hr postdose; ③, Phonophobia freedom 2 hr postdose; ④, Photophobia freedom 2 hr postdose; ⑤, Any adverse events; ⑥, Treatment‐related adverse events; ⑦, Abnormal liver function; ⑧, Chest discomfort.